Vizient Predicts Nearly 7.5 Percent Increase In Drug Prices, Says Biosimilars Are The Solution

February 6, 2018 at 12:53 PM

Group Purchasing Organization Vizient expects drug prices to increase 7.35 percent from July 2018 through June 2019, with the most substantial price hikes occurring in disease-modifying anti-rheumatic agents, like Remicade, Humira and Enbrel.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.